Thyro-pro Liquid
NDC Package 71742-0013-1
Package Information
Thyro-pro (fucus vesiculosus, spongia tosta, glandula suprarenalis suis, hypophysis suis, thyroidinum (suis), bromium, calcarea carbonica, iodium, lachesis mutus, pulsatilla (vulgaris)) liquids is thymus support, immune system booster. This formulation utilizes a liquid delivery system. Marketed by Guangzhou Renuma Medical Systems Co., Ltd, this product is identified by NDC 71742-0013.
Identification & Billing
Clinical Specifications
- BROMINE 12 [hp_X]/mL
- FUCUS VESICULOSUS 3 [hp_X]/mL
- IODINE 12 [hp_X]/mL
- LACHESIS MUTA VENOM 12 [hp_X]/mL
- OYSTER SHELL CALCIUM CARBONATE, CRUDE 12 [hp_X]/mL
- PULSATILLA VULGARIS 12 [hp_X]/mL
- SPONGIA OFFICINALIS SKELETON, ROASTED 3 [hp_X]/mL
- SUS SCROFA ADRENAL GLAND 6 [hp_X]/mL
- SUS SCROFA PITUITARY GLAND 6 [hp_X]/mL
- SUS SCROFA THYROID 6 [hp_X]/mL
Regulatory & Marketing
Hierarchy Structure
- 71742 - Guangzhou Renuma Medical Systems Co., Ltd
- 71742-0013 - Thyro-pro
- 71742-0013-1 - 59 mL in 1 BOTTLE, DROPPER
- 71742-0013 - Thyro-pro
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 71742-0013-1 identifies a specific commercial package of 59 ml in 1 bottle, dropper of Thyro-pro T019, a human over the counter drug labeled by Guangzhou Renuma Medical Systems Co., Ltd. This liquid is formulated for oral use and contains bromine; fucus vesiculosus; iodine; lachesis muta venom; oyster shell calcium carbonate, crude; pulsatilla vulgaris; spongia officinalis skeleton, roasted; sus scrofa adrenal gland; sus scrofa pituitary gland; sus scrofa thyroid as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Guangzhou Renuma Medical Systems Co., Ltd on October 26, 2017. The current certification is valid through December 31, 2026.
How is this Guangzhou Renuma Medical Systems Co., Ltd product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 71742001301. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.